Evolocumab Reduces First Cardiovascular Events in High-Risk Diabetes

Expanding Primary Prevention in High-Risk Diabetes

Patients with diabetes mellitus face a disproportionately high risk of atherosclerotic cardiovascular disease, driven largely by the causal relationship between cumulative exposure to low-density lipoprotein cholesterol and vascular injury [1, 2]. While statins remain the first-line therapy for risk reduction, many patients continue to experience major adverse cardiovascular events (a composite of myocardial infarction, stroke, and cardiovascular death) despite reaching traditional lipid targets [3, 4]. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as evolocumab and alirocumab, reduce the risk of these major events by approximately 18% in patients with diabetes (odds ratio 0.82; 95% confidence interval, 0.74 to 0.90) [1, 5]. However, clinical guidelines have historically reserved these potent agents for secondary prevention in patients with established, symptomatic atherosclerosis [6, 7, 8]. A recent study, the VESALIUS-CV trial, investigates whether initiating evolocumab earlier in the disease continuum can prevent the first occurrence of major cardiovascular complications in high-risk patients with diabetes who have no prior history of myocardial infarction or stroke, potentially shifting how clinicians approach primary prevention in this vulnerable population [9].

Trial Design and Patient Selection

The VESALIUS-CV trial was a randomized, double-blind, placebo-controlled study conducted across 774 sites in 33 countries. The researchers enrolled a total of 12,257 patients who had no history of prior myocardial infarction or stroke and maintained low-density lipoprotein cholesterol (LDL-C) levels of 90 mg/dL or greater. This specific analysis focused on a prespecified subgroup of 3,655 patients with diabetes who did not have known significant atherosclerosis. To ensure the cohort represented a true primary prevention population, the study excluded any individuals with a history of arterial revascularization, arterial stenosis of 50% or greater, or a coronary artery calcium score (a computed tomography imaging metric used to quantify calcified plaque burden in the coronary arteries) of 100 Agatston units or greater. By excluding these patients, the investigators isolated a cohort that allowed them to test whether aggressive lipid lowering benefits patients before structural heart disease becomes clinically apparent.

Within this subgroup, 1,849 patients were randomized to receive subcutaneous evolocumab at a dose of 140 mg every 2 weeks, while 1,806 patients received a matching placebo. All participants received the study intervention as an adjunct to optimally tolerated statin therapy. The cohort had a median age of 65 years and was 57% female. Enrollment for the trial began in June 2019, and the final patient visit was completed in July 2025. Over a median follow-up period of 4.8 years, the researchers monitored these high-risk patients to determine if intensive lipid lowering could prevent the first occurrence of major cardiovascular events in the absence of established obstructive disease.

Lipid Reduction and Primary MACE Outcomes

The researchers evaluated the efficacy of evolocumab by first measuring its impact on lipid profiles within a dedicated substudy. Among those participants, the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group compared to 111 mg/dL in the placebo group (P < .001). This significant reduction in low-density lipoprotein cholesterol established the physiological foundation for the trial's primary clinical assessments. To measure the impact of this reduction on clinical outcomes, the study utilized dual primary end points. These were defined as 3-P MACE (a composite of coronary heart disease death, myocardial infarction, or ischemic stroke) and 4-P MACE, which consisted of the 3-P MACE components plus ischemia-driven arterial revascularization (stenting or bypass surgery required to restore blood flow due to symptomatic arterial narrowing).

The addition of evolocumab to background statin therapy resulted in a statistically significant reduction in the primary clinical outcome over the follow-up period. A 3-P MACE event occurred in 83 patients in the evolocumab group, representing a 5-year Kaplan-Meier estimate (a statistical method that calculates the probability of an event occurring over a specific time period while accounting for patient dropout) of 5.0%. In contrast, 117 patients in the placebo group experienced a 3-P MACE event, resulting in a 5-year Kaplan-Meier estimate of 7.1%. This yielded a hazard ratio for 3-P MACE of 0.69 (95% CI, 0.52-0.91; P = .009), reflecting a 31% relative risk reduction. The absolute between-group difference for 3-P MACE was 2.1% (95% CI, 0.4%-3.8%). For practicing physicians, this demonstrates that intensifying lipid therapy beyond statins can meaningfully alter the natural history of cardiovascular disease in diabetic patients before their first heart attack or stroke.

Impact on Revascularization and All-Cause Mortality

The clinical benefit of evolocumab extended beyond the prevention of myocardial infarction and stroke to include a reduction in the need for invasive vascular procedures. When evaluating the broader 4-P MACE composite endpoint, which adds ischemia-driven arterial revascularization to the 3-P MACE components, a 4-P MACE event occurred in 127 patients in the evolocumab group compared with 178 patients in the placebo group. The 5-year Kaplan-Meier estimates for these events were 7.6% and 10.5%, respectively. This resulted in a hazard ratio for 4-P MACE of 0.69 (95% CI, 0.55-0.86; P = .001), representing a 31% reduction in the relative risk of major events or revascularization. The absolute between-group difference for 4-P MACE was 2.9% (95% CI, 0.9%-4.9%). In clinical terms, this absolute risk reduction suggests that for every 100 high-risk patients with diabetes treated with evolocumab for five years, approximately three major cardiovascular events or revascularization procedures could be avoided.

The trial also assessed the impact of intensive lipid lowering on survival through the secondary end point of all-cause mortality. During the median follow-up of 4.8 years, there were 136 deaths in the evolocumab group compared with 172 deaths in the placebo group. These figures correspond to 5-year Kaplan-Meier estimates of 7.8% for patients receiving evolocumab and 10.1% for those receiving placebo. The hazard ratio for all-cause mortality was 0.76 (95% CI, 0.61-0.95), indicating a lower risk of death from any cause among patients randomized to the PCSK9 inhibitor. These findings underscore the potential for early, intensive low-density lipoprotein cholesterol reduction to improve long-term survival in patients with diabetes who have not yet developed symptomatic or significant atherosclerotic disease, offering a compelling rationale to reconsider the threshold for initiating advanced lipid-lowering therapies in primary care.

References

1. Imbalzano E, Ilardi F, Orlando L, Pintaudi B, Savarese G, Rosano G. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.. European heart journal. Cardiovascular pharmacotherapy. 2023. doi:10.1093/ehjcvp/pvad019

2. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal. 2017. doi:10.1093/eurheartj/ehx144

3. Reith C, Baigent C, Blackwell L, et al. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet. 2022. doi:10.1016/s0140-6736(22)01545-8

4. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.. Journal of the American College of Cardiology. 2019. doi:10.1016/j.jacc.2018.11.004

5. Orlando L, Quartuccio S, Vatrano M, Imbalzano E. P363 EFFECTS OF ALIROCUMAB AND EVOLOCUMAB ON THE OUTCOMES AND LIPID PROFILE OF DIABETIC PATIENTS: META–ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. European Heart Journal, Supplement. 2023. doi:10.1093/eurheartjsupp/suad111.436

6. Sabatine MS, Giugliano RP, Keech A, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017. doi:10.1056/nejmoa1615664

7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz455

8. Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.. Circulation. 2019. doi:10.1161/CIR.0000000000000626

9. Bohula EA, Marston NA, Ruzza A, et al. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.. American heart journal. 2024. doi:10.1016/j.ahj.2023.12.004